MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597988 | Name: Sdz 215-811

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sdz 215-811 is a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors.

Chemical Structure

Sdz 215-811
Sdz 215-811
CAS#142694-57-3

Theoretical Analysis

MedKoo Cat#: 597988

Name: Sdz 215-811

CAS#: 142694-57-3

Chemical Formula: C63H85N13O20S2

Exact Mass: 1407.5475

Molecular Weight: 1408.56

Elemental Analysis: C, 53.72; H, 6.08; N, 12.93; O, 22.72; S, 4.55

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sdz 215-811; Sdz-215-811; Sdz215-811; Octreoscan 111; Pentatreotide;
IUPAC/Chemical Name
L-Threonine, N-(2-((2-(bis(carboxymethyl)amino)ethyl)(carboxymethyl)amino)ethyl)-N-(carboxymethyl)glycyl-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryprophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (3-8)-disulfide
InChi Key
DSCDMAQBPMKHAS-UHFFFAOYSA-N
InChi Code
1S/C63H85N13O20S2/c1-36(77)54-62(94)71-48(61(93)73-55(37(2)78)63(95)96)35-98-97-34-47(70-57(89)44(25-38-13-5-3-6-14-38)66-49(79)29-75(31-51(82)83)23-21-74(30-50(80)81)22-24-76(32-52(84)85)33-53(86)87)60(92)68-45(26-39-15-7-4-8-16-39)58(90)69-46(27-40-28-65-42-18-10-9-17-41(40)42)59(91)67-43(56(88)72-54)19-11-12-20-64/h3-10,13-18,28,36-37,43-48,54-55,65,77-78H,11-12,19-27,29-35,64H2,1-2H3,(H,66,79)(H,67,91)(H,68,92)(H,69,90)(H,70,89)(H,71,94)(H,72,88)(H,73,93)(H,80,81)(H,82,83)(H,84,85)(H,86,87)(H,95,96)
SMILES Code
O[C@@H](C)[C@@H](C(N[C@H](C(N[C@H](C(O)=O)[C@H](O)C)=O)CSSC[C@H](NC([C@H](NC(CN(CCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O)CC(O)=O)=O)Cc1ccccc1)=O)C(N[C@H](C(N2)=O)Cc3ccccc3)=O)=O)NC([C@@H](CCCCN)NC([C@H]2Cc4c(cccc5)c5[nH]c4)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,408.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bruns C, Stolz B, Albert R, Marbach P, Pless J. OctreoScan 111 for imaging of a somatostatin receptor-positive islet cell tumor in rat. Horm Metab Res Suppl. 1993;27:5-11. PubMed PMID: 8392488. 2: Hardiansyah D, Begum NJ, Kletting P, Mottaghy FM, Glatting G. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy. Cancer Biother Radiopharm. 2016 Aug;31(6):217-24. doi: 10.1089/cbr.2016.2012. Epub 2016 Jul 12. PubMed PMID: 27403777. 3: Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, et al. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991;49(22):1583-91. PubMed PMID: 1658515. 4: Harrison CE, Barron BJ. MIBG superscan of metastatic paraganglioma occurring with neurofibromatosis type 1. Clin Nucl Med. 2013 Jun;38(6):459-62. doi: 10.1097/RLU.0b013e3182816777. PubMed PMID: 23455526. 5: Laverman P, Sosabowski JK, Boerman OC, Oyen WJ. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S78-92. doi: 10.1007/s00259-011-2014-7. Review. PubMed PMID: 22388627; PubMed Central PMCID: PMC3304069. 6: Bomanji JB, Papathanasiou ND. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S113-25. doi: 10.1007/s00259-011-2013-8. Review. PubMed PMID: 22388626. 7: Kletting P, Muller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, Mottaghy FM, Glatting G. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys. 2012 Sep;39(9):5708-17. PubMed PMID: 22957636. 8: Spieth ME, Vasinrapee P. Ga-67 and In-111 pentreotide imaging. Clin Nucl Med. 1996 Jan;21(1):80. PubMed PMID: 8741905. 9: Banzo J, Prats E, Razola P, Tardín L, Benito JL, Andrés A, Santapau A. [111In-DTPAOC SPECT-CT in radiation pulmonary fibrosis]. Rev Esp Med Nucl. 2009 Mar-Apr;28(2):81-2. Spanish. PubMed PMID: 19406056. 10: Walrand S, Barone R, Pauwels S, Jamar F. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1270-80. doi: 10.1007/s00259-011-1744-x. Epub 2011 Feb 12. PubMed PMID: 21318451. 11: Lamberts SW, Reubi JC, Krenning EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol. 1994 Oct;21(5 Suppl 13):1-5. Review. PubMed PMID: 7992074. 12: Decristoforo C, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R, Mather SJ. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000 Oct;27(10):1580. PubMed PMID: 11083550. 13: Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010 Jun;51(6):875-82. doi: 10.2967/jnumed.109.066134. Epub 2010 May 19. PubMed PMID: 20484441. 14: Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci. 1994 Sep 15;733:416-24. Review. PubMed PMID: 7978890. 15: Guneri EA, Degirmenci B, Durak H, Ikiz AO, Derebek E, Sutay S. Indium 111 octreotide scintigraphy in angiofibroma. Otolaryngol Head Neck Surg. 1998 Jan;118(1):137-9. PubMed PMID: 9450844. 16: Colao A, Pivonello R, Lastoria S, Faggiano A, Ferone D, Lombardi G, Fenzi G. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. Eur J Endocrinol. 2000 Oct;143 Suppl 1:S35-42. Review. PubMed PMID: 11068938. 17: Chamberlain MC, Kormanik P, Jaeckle KA, Glantz M. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1999 Jan 1;52(1):216-7. PubMed PMID: 9921888. 18: Müssig K, Oksüz MO, Dudziak K, Ueberberg B, Wehrmann M, Horger M, Schulz S, Häring HU, Pfannenberg C, Bares R, Gallwitz B, Petersenn S. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors. Horm Metab Res. 2010 Jul;42(8):599-606. doi: 10.1055/s-0030-1253354. Epub 2010 Apr 26. PubMed PMID: 20422506. 19: Gulec SA, Serafini AN, Sridhar KS, Peker KR, Gupta A, Goodwin WJ, Sfakianakis GN, Moffat FL. Somatostatin receptor expression in Hürthle cell cancer of the thyroid. J Nucl Med. 1998 Feb;39(2):243-5. PubMed PMID: 9476928. 20: Müssig K, Oksüz MO, Pfannenberg C, Adam P, Zustin J, Beckert S, Petersenn S. Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia. J Clin Endocrinol Metab. 2009 Nov;94(11):4123-4. doi: 10.1210/jc.2009-0927. Epub 2009 Sep 29. PubMed PMID: 19789203.

View History

Lerimazoline HCl

Lerimazoline HCl